Highlights Newsletter 3
This newsletter presents you the following key sessions:
1. PODCAST with prof. Tiziano Barbui about ropeginterferon in patients with polycythemia vera
2. Ibrutinib plus venetoclax confers high rates of undetectable minimal residual disease in the first-line treatment
of chronic lymphocytic leukaemia
3. Similar safety and efficacy of azacitidine and decitabine in patients with treatment-naïve acute myeloid leukaemia
who are ineligible for intensive chemotherapy
4. Oral selinexor proves to be safe and effective in patients with primary refractory diffuse large B-cell lymphoma
5. Adding isatuximab to carfilzomib and dexamethasone significantly delays the disease progression of patients
with relapsed/refractory multiple myeloma

